08-16-2017, 10:57 PM
abstract
The advent of nanotechnology in cancer research couldn t have come at a more opportune time. The vast knowledge of cancer genomics and proteomics emerging as a result of the Human Genome Project is providing critically important details of how cancer develops, which in turn creates new opportunities to attack the molecular underpinnings of cancer. However, scientists lack the technological innovations to turn promising molecular discoveries into benefits for cancer patients. It is here that nanotechnology can play a pivotal role, providing the technological power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today s explosion in knowledge.
Nanotechnology provides the sized materials that can be synthesized and function in the same general size range and Biologic structures. Attempts are made to develop forms of anticancer therapeutics based on nanomaterials. Dendritic polymer nanodevices serves as a means for the detection of cancer cells, the identification of cancer signatures, and the targeted delivery of anti-cancer therapeutics (cis-platin, methotrexate, and taxol) and contrast agents to tumor cells. Initial studies documented the synthesis and function of a targeting module, several drug delivery components, and two imaging/contrast agents. Analytical techniques have been developed and used to confirm the structure of the device. Progress has been made on the specifically triggered release of the therapeutic agent within a tumor using high-energy lasers. The work to date has demonstrated the feasibility of the nano-device concept in actual cancer cells in vitro.